Pfizer’s RSV Vaccine Shows Efficacy In Older Adults, Setting Up Showdown With GSK

 
• By Joseph Haas

Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.

RSV illustration
Pfizer is readying a BLA filing for its RSV vaccine candidate • Source: Shutterstock

More from Clinical Trials

More from R&D